TN2010000068A1 - Anticorps anti-cd37 - Google Patents

Anticorps anti-cd37

Info

Publication number: TN2010000068A1
Authority: TN; Tunisia
Prior art keywords: cellules; anticorps anti; les; des; humanisés
Prior art date: 2007-08-09

Application number

TNP2010000068A

Other languages

English (en)

Inventor

Karl Hein Heider

Eric Borges

Elinborg Ostermann

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-08-09

Filing date

2010-02-08

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000068(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-08 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2011-09-26 Publication of TN2010000068A1 publication Critical patent/TN2010000068A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Environmental Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

TNP2010000068A 2007-08-09 2010-02-08 Anticorps anti-cd37 TN2010000068A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07114128		2007-08-09
PCT/EP2008/060464 WO2009019312A2 (fr)	2007-08-09	2008-08-08	Anticorps anti-cd37

Publications (1)

Publication Number	Publication Date
TN2010000068A1 true TN2010000068A1 (en)	2011-09-26

Family

ID=38925567

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000068A TN2010000068A1 (en)	2007-08-09	2010-02-08	Anticorps anti-cd37

Country Status (37)

Country	Link
US (7)	US20100189722A1 (fr)
EP (3)	EP2178915B1 (fr)
JP (3)	JP5325216B2 (fr)
KR (1)	KR101593403B1 (fr)
CN (4)	CN103396490A (fr)
AR (2)	AR071242A1 (fr)
AU (1)	AU2008285590B2 (fr)
BR (2)	BRPI0823331A2 (fr)
CA (1)	CA2693464C (fr)
CL (3)	CL2008002349A1 (fr)
CO (1)	CO6251371A2 (fr)
CY (1)	CY1117101T1 (fr)
DK (1)	DK2178915T3 (fr)
EA (2)	EA027499B1 (fr)
EC (2)	ECSP109946A (fr)
ES (1)	ES2555202T3 (fr)
HK (1)	HK1220708A1 (fr)
HR (1)	HRP20160009T1 (fr)
HU (1)	HUE026221T2 (fr)
IL (1)	IL202645A (fr)
MA (1)	MA32665B1 (fr)
ME (1)	ME02300B (fr)
MY (1)	MY157555A (fr)
NZ (2)	NZ583713A (fr)
PE (3)	PE20120259A1 (fr)
PH (1)	PH12014501812B1 (fr)
PL (1)	PL2178915T3 (fr)
PT (1)	PT2178915E (fr)
RS (1)	RS54359B1 (fr)
SG (1)	SG190657A1 (fr)
SI (1)	SI2178915T1 (fr)
TN (1)	TN2010000068A1 (fr)
TW (2)	TW201512220A (fr)
UA (2)	UA105445C2 (fr)
UY (1)	UY31275A1 (fr)
WO (1)	WO2009019312A2 (fr)
ZA (1)	ZA200908758B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
DK2298815T3 (en)	2005-07-25	2015-06-15	Emergent Product Dev Seattle	B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
MX363905B (es)	2006-06-12	2019-04-08	Aptevo Res & Development Llc	Proteinas de union multivalentes monocatenarias con funcion efectora.
PE20120259A1 (es) *	2007-08-09	2012-04-04	Boehringer Ingelheim Int	Anticuerpos anti-cd37
EP2205077A4 (fr) *	2007-09-24	2010-12-29	Tragara Pharmaceuticals Inc	Thérapies pour traiter le cancer en utilisant des combinaisons d'inhibiteurs de cox-2 et des anticorps anti-her2(erbb2) ou des combinaisons d'inhibiteurs de cox-2 et des inhibiteurs du récepteur her2(erbb2) de la tyrosine kinase
ATE513856T1 (de)	2008-04-11	2011-07-15	Emergent Product Dev Seattle	Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
ES2573642T3 (es) *	2009-12-23	2016-06-09	Synimmune Gmbh	Anticuerpos anti-FLT3 y métodos de usar los mismos
NO331080B1 (no)	2010-01-29	2011-09-26	Nordic Nanovector As	Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
HUE046360T2 (hu) *	2010-03-12	2020-03-30	Debiopharm Int Sa	CD37-kötõ molekulák és azok immunkonjugátumai
US20120189618A1 (en) *	2010-07-16	2012-07-26	Boehringer Ingelheim International Gmbh	Superior efficacy of cd37 antibodies in cll blood samples
UA112062C2 (uk)	2010-10-04	2016-07-25	Бьорінгер Інгельхайм Інтернаціональ Гмбх	Cd33-зв'язувальний агент
US20120107317A1 (en) *	2010-10-27	2012-05-03	The University Of Hong Kong	Use of cytoplasmic c-myc for regulating immune responses
CA2831111A1 (fr) *	2011-04-01	2012-10-04	Immunogen, Inc.	Molecules liant cd37 et immunoconjugues de celles-ci
WO2012158818A2 (fr)	2011-05-16	2012-11-22	Fabion Pharmaceuticals, Inc.	Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
US20140348745A1 (en) *	2011-12-13	2014-11-27	Nordic Nanovector As	Chimeric therapeutic anti - cd37 antibodie hh1
RU2014140119A (ru) *	2012-03-30	2016-05-27	Иммьюноджен, Инк.	Способы повышения эффективности терапии на основе cd37
US20130287797A1 (en) *	2012-04-26	2013-10-31	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with bendamustine
US20130309224A1 (en) *	2012-05-16	2013-11-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with rituximab
US8992915B2 (en) *	2012-05-16	2015-03-31	Boehringer Ingelheim International Gmbh	Combination of CD37 antibodies with ICE
US9539259B2 (en) *	2012-05-23	2017-01-10	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
WO2014151438A1 (fr) *	2013-03-15	2014-09-25	Emergent Product Development Seattle, Llc	Anticorps anti-cd37 multispécifiques, compositions et méthodes s'y rapportant
US20160106837A1 (en) *	2013-06-14	2016-04-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with chlorambucil
EP3027220A1 (fr)	2013-08-01	2016-06-08	Agensys, Inc.	Conjugués anticorps-médicament (adc) se liant à la protéine cd37
US9291244B2 (en)	2014-01-17	2016-03-22	Ford Global Technologies, Llc	Nine speed automatic transmission
EP2966085A1 (fr)	2014-07-11	2016-01-13	Boehringer Ingelheim International GmbH	Anticorps de type IgG1 ayant une chaîne constante lourde modifiée
MA44594B1 (fr)	2015-05-29	2020-09-30	Memorial Sloan Kettering Cancer Center	Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
UA125496C2 (uk)	2015-06-08	2022-04-13	Дебіофарм Інтернаціонал, С.А.	Спосіб лікування пацієнта з в-клітинним раком імунокон’югатом, який зв’язується з cd37 разом з антитілом, що зв'язується з cd20
SI3124976T1 (sl)	2015-07-28	2018-12-31	F. Hoffmann-La Roche Ag	Izboljšan test bakterijskih endotoksinov za določanje endotoksinov
EP3341414A4 (fr)	2015-08-28	2019-03-27	Debiopharm International SA	Anticorps et dosages pour la détection de cd37
WO2017053469A2 (fr)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Polypeptides de liaison à cd3
CN109476756B (zh)	2016-03-15	2022-05-31	埃泰美德(香港)有限公司	一种多特异性Fab融合蛋白及其用途
JP2020510608A (ja)	2016-11-02	2020-04-09	デビオファームインターナショナル，エス．アー．	抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
IL307242A (en) *	2016-12-07	2023-11-01	Agenus Inc	Anti-CTLA-4 antibodies and methods of using them
US11578115B2 (en)	2017-01-10	2023-02-14	The General Hospital Corporation	Chimeric antigen receptors based on alternative signal 1 domains
CA3056115A1 (fr)	2017-03-16	2018-09-20	The General Hospital Corporation	Recepteurs d'antigenes chimeriques ciblant cd37
CA3057907A1 (fr)	2017-03-31	2018-10-04	Genmab Holding B.V.	Anticorps anti-cd37 bispecifiques, anticorps anti-cd37 monoclonaux et leurs methodes d'utilisation
CN110996658B (zh)	2017-06-27	2024-03-26	瑞泽恩制药公司	包含人源化asgr1基因座的非人动物
JP2021525735A (ja)	2018-05-30	2021-09-27	デビオファームインターナショナル，エス．アー．	抗ｃｄ３７免疫コンジュゲート投薬レジメン
WO2019246546A1 (fr) *	2018-06-22	2019-12-26	The General Hospital Corporation	Récepteurs antigéniques chimériques ciblant cd37 et cd19
WO2019243636A1 (fr)	2018-06-22	2019-12-26	Genmab Holding B.V.	Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
WO2020004337A1 (fr) *	2018-06-27	2020-01-02	国立大学法人名古屋大学	Récepteur antigénique chimérique spécifique à cd37
WO2020048525A1 (fr)	2018-09-07	2020-03-12	Generon (Shanghai) Corporation Ltd.	Protéines de liaison à un antigène bispécifiques et leurs utilisations
US20240252635A1 (en)	2018-10-04	2024-08-01	Genmab Holding B.V.	Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
EP4021579A1 (fr) *	2019-08-30	2022-07-06	Qilu Puget Sound Biotherapeutics Corporation	Anticorps anti-cd20, anticorps anti-cd37 et leurs mélanges
CN118339188A (zh)	2021-09-21	2024-07-12	齐鲁普吉湾生物治疗公司	用于制备融合蛋白和双特异性抗体的异二聚体Fc
US20250333531A1 (en)	2021-10-06	2025-10-30	Nordic Nanovector Asa	Humanized hh1
WO2023057595A1 (fr)	2021-10-06	2023-04-13	Nordic Nanovector Asa	Hh1 rew humanisé
MX2024004048A (es) *	2021-10-18	2024-04-25	Daiichi Sankyo Co Ltd	Conjugado anticuerpo-farmaco anti-cd37.
WO2024118480A1 (fr) *	2022-11-28	2024-06-06	Epiphany Biosciences	Utilisation d'agents antiviraux, composition de matière, préparations/agents de combinaison pour traiter des maladies chroniques associées au virus d'epstein-barr et à d'autres virus de l'herpès humain
WO2025083205A1 (fr)	2023-10-18	2025-04-24	Debiopharm International S.A.	Combinaison médicamenteuse incluant un anticorps anti-cd37 conjugué à la maytansine et un inhibiteur de bcl2 ou un inhibiteur de pi3k
WO2025149667A1 (fr)	2024-01-12	2025-07-17	Pheon Therapeutics Ltd	Conjugués anticorps-médicament et leurs utilisations

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4342566A (en)	1980-02-22	1982-08-03	Scripps Clinic & Research Foundation	Solid phase anti-C3 assay for detection of immune complexes
JPS63501765A (ja)	1985-11-01	1988-07-21	インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド	抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) *	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
GB8800077D0 (en) *	1988-01-05	1988-02-10	Ciba Geigy Ag	Novel chimeric antibodies
DE68908175T2 (de)	1988-05-27	1994-03-03	Centocor Inc	Gefriergetrocknete formulierung für antikörperprodukte.
WO1990002569A1 (fr) *	1988-09-06	1990-03-22	International Genetic Engineering, Inc.	Production d'anticorps chimeriques murins-humains a specificite pour des antigenes de tumeurs humains
ES2238070T3 (es)	1989-04-21	2005-08-16	Amgen Inc.	Receptor del tnf, proteina ligante del tnf y adn codante para estos.
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2193136T3 (es)	1991-08-14	2003-11-01	Genentech Inc	Variantes de inmunoglubina para receptores especificos de fc epsilon.
CA2076465C (fr)	1992-03-25	2002-11-26	Ravi V. J. Chari	Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
ES2108460T3 (es)	1993-06-03	1997-12-16	Therapeutic Antibodies Inc	Fragmentos de anticuerpos en terapeutica.
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
WO1997034631A1 (fr)	1996-03-18	1997-09-25	Board Of Regents, The University Of Texas System	Domaines analogues a l'immunoglobuline a demi-vies prolongees
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CA2262405A1 (fr)	1996-08-02	1998-02-12	Bristol-Myers Squibb Company	Procede servant a inhiber la toxicite provoquee par les immunoglobulines provenant de l'utilisation d'immunoglobulines en therapie et en diagnostic in vivo
US6991790B1 (en)	1997-06-13	2006-01-31	Genentech, Inc.	Antibody formulation
BR9908226A (pt)	1998-02-25	2000-10-24	Lexigen Pharm Corp	Melhoramento da meia vida de circulação de proteìnas de fusão com base em anticorpo
DE19911329A1 (de)	1998-03-27	2000-09-21	Benes Ivan Friedrich	Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
CA2323757C (fr)	1998-04-02	2011-08-02	Genentech, Inc.	Variants d'anticorps et fragments de ceux-ci
GB9809951D0 (en)	1998-05-08	1998-07-08	Univ Cambridge Tech	Binding molecules
DK1242401T3 (da)	1999-11-24	2007-05-07	Immunogen Inc	Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
PT1242438E (pt)	1999-12-29	2007-02-28	Immunogen Inc	Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico
PT1355919E (pt)	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US20030133939A1 (en) *	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en)	2001-12-21	2004-04-06	Immunogen Inc.	Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
CN100522999C (zh) *	2002-02-14	2009-08-05	免疫医疗公司	抗cd20抗体及其融合蛋白和使用方法
US20040002587A1 (en)	2002-02-20	2004-01-01	Watkins Jeffry D.	Fc region variants
AU2003217912A1 (en)	2002-03-01	2003-09-16	Xencor	Antibody optimization
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US6756397B2 (en)	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
US6596757B1 (en)	2002-05-14	2003-07-22	Immunogen Inc.	Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
AU2003262650B2 (en)	2002-08-14	2009-10-29	Macrogenics, Inc.	FcgammaRIIB-specific antibodies and methods of use thereof
AU2003259835A1 (en)	2002-08-15	2004-03-03	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to trail receptors
CA2832136C (fr)	2002-09-27	2015-11-17	Xencor	Variants fc optimises et methodes destinees a leur generation
JP4768439B2 (ja)	2002-10-15	2011-09-07	アボットバイオセラピューティクスコーポレイション	変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
US7960512B2 (en)	2003-01-09	2011-06-14	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204494B2 (en)	2003-01-09	2011-09-29	Macrogenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004247015B2 (en)	2003-05-14	2010-12-16	Immunogen, Inc.	Drug conjugate composition
US7754209B2 (en)	2003-07-26	2010-07-13	Trubion Pharmaceuticals	Binding constructs and methods for use thereof
US20070148170A1 (en)	2005-10-03	2007-06-28	Desjarlais John R	Fc Variants With Optimized Fc Receptor Binding Properties
WO2005077981A2 (fr)	2003-12-22	2005-08-25	Xencor, Inc.	Polypeptides fc a nouveaux sites de liaison de ligands fc
EP1737890A2 (fr)	2004-03-24	2007-01-03	Xencor, Inc.	Variantes d'immunoglobuline a l'exterieur de la region fc
KR100863776B1 (ko)	2004-07-15	2008-10-16	젠코어 인코포레이티드	최적화된 Ｆｃ 변이체
US20060074225A1 (en)	2004-09-14	2006-04-06	Xencor, Inc.	Monomeric immunoglobulin Fc domains
WO2006047350A2 (fr)	2004-10-21	2006-05-04	Xencor, Inc.	Variants d'immunoglobuline igg a fonction effectrice optimisee
BRPI0517837A (pt)	2004-11-12	2008-10-21	Xencor Inc	variantes fc com ligação alterada a fcrn
DK2298815T3 (en) *	2005-07-25	2015-06-15	Emergent Product Dev Seattle	B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES
US20080279850A1 (en)	2005-07-25	2008-11-13	Trubion Pharmaceuticals, Inc.	B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
CA2625681C (fr)	2005-10-12	2016-08-02	Morphosys Ag	Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
EP1806365A1 (fr)	2006-01-05	2007-07-11	Boehringer Ingelheim International GmbH	Anticorps spécifiques pour la protéine alpha d'activation de fibroblastes et leurs immunoconjugués
CN101990439A (zh)	2007-07-06	2011-03-23	特鲁比昂药品公司	具有置于c末端的特异性结合结构域的结合肽
PE20120259A1 (es) *	2007-08-09	2012-04-04	Boehringer Ingelheim Int	Anticuerpos anti-cd37
ATE513856T1 (de)	2008-04-11	2011-07-15	Emergent Product Dev Seattle	Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
UA108735C2 (uk)	2008-07-21	2015-06-10		Структурні варіанти антитіл для покращення терапевтичних характеристик
CA2743487A1 (fr)	2008-11-13	2010-05-20	Emergent Product Development Seattle, Llc	Therapies d'association immunotherapeutique cd37 et utilisations de celles-ci
US20120189618A1 (en) *	2010-07-16	2012-07-26	Boehringer Ingelheim International Gmbh	Superior efficacy of cd37 antibodies in cll blood samples
US20130287797A1 (en) *	2012-04-26	2013-10-31	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with bendamustine
US8992915B2 (en) *	2012-05-16	2015-03-31	Boehringer Ingelheim International Gmbh	Combination of CD37 antibodies with ICE
US20130309224A1 (en) *	2012-05-16	2013-11-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with rituximab
US20160106837A1 (en)	2013-06-14	2016-04-21	Boehringer Ingelheim International Gmbh	Combination of cd37 antibodies with chlorambucil

2008
- 2008-08-07 PE PE2011000972A patent/PE20120259A1/es active IP Right Grant
- 2008-08-07 PE PE2008001321A patent/PE20090499A1/es active IP Right Grant
- 2008-08-07 PE PE2013000843A patent/PE20140196A1/es not_active Application Discontinuation
- 2008-08-08 WO PCT/EP2008/060464 patent/WO2009019312A2/fr not_active Ceased
- 2008-08-08 AR ARP080103490A patent/AR071242A1/es not_active Application Discontinuation
- 2008-08-08 PL PL08787055T patent/PL2178915T3/pl unknown
- 2008-08-08 CN CN2013102616193A patent/CN103396490A/zh active Pending
- 2008-08-08 CN CN2011102205939A patent/CN102276724A/zh active Pending
- 2008-08-08 PT PT87870556T patent/PT2178915E/pt unknown
- 2008-08-08 EP EP08787055.6A patent/EP2178915B1/fr active Active
- 2008-08-08 JP JP2010519473A patent/JP5325216B2/ja active Active
- 2008-08-08 EA EA201000274A patent/EA027499B1/ru not_active IP Right Cessation
- 2008-08-08 EP EP12185691.8A patent/EP2562187B1/fr active Active
- 2008-08-08 UA UAA201303569A patent/UA105445C2/uk unknown
- 2008-08-08 CL CL2008002349A patent/CL2008002349A1/es unknown
- 2008-08-08 BR BRPI0823331-4A2A patent/BRPI0823331A2/pt not_active Application Discontinuation
- 2008-08-08 SG SG2013037619A patent/SG190657A1/en unknown
- 2008-08-08 MY MYPI2010000565A patent/MY157555A/en unknown
- 2008-08-08 HR HRP20160009TT patent/HRP20160009T1/hr unknown
- 2008-08-08 DK DK08787055.6T patent/DK2178915T3/en active
- 2008-08-08 ME MEP-2015-191A patent/ME02300B/me unknown
- 2008-08-08 EP EP10168244A patent/EP2241577A1/fr not_active Withdrawn
- 2008-08-08 NZ NZ583713A patent/NZ583713A/en not_active IP Right Cessation
- 2008-08-08 AU AU2008285590A patent/AU2008285590B2/en not_active Ceased
- 2008-08-08 UY UY31275A patent/UY31275A1/es not_active Application Discontinuation
- 2008-08-08 TW TW103121994A patent/TW201512220A/zh unknown
- 2008-08-08 CN CN200880102642A patent/CN101815725A/zh active Pending
- 2008-08-08 NZ NZ600022A patent/NZ600022A/xx not_active IP Right Cessation
- 2008-08-08 ES ES08787055.6T patent/ES2555202T3/es active Active
- 2008-08-08 UA UAA201002500A patent/UA103005C2/ru unknown
- 2008-08-08 BR BRPI0815369-8A patent/BRPI0815369A2/pt active Search and Examination
- 2008-08-08 KR KR1020107002636A patent/KR101593403B1/ko not_active Expired - Fee Related
- 2008-08-08 CA CA2693464A patent/CA2693464C/fr not_active Expired - Fee Related
- 2008-08-08 RS RS20150817A patent/RS54359B1/sr unknown
- 2008-08-08 TW TW097130378A patent/TWI535733B/zh not_active IP Right Cessation
- 2008-08-08 HU HUE08787055A patent/HUE026221T2/en unknown
- 2008-08-08 SI SI200831544T patent/SI2178915T1/sl unknown
- 2008-08-08 EA EA201200994A patent/EA201200994A1/ru unknown
- 2008-08-08 CN CN201510756148.2A patent/CN105273086A/zh active Pending
- 2008-08-08 US US12/672,378 patent/US20100189722A1/en not_active Abandoned
2009
- 2009-12-09 ZA ZA200908758A patent/ZA200908758B/xx unknown
- 2009-12-10 IL IL202645A patent/IL202645A/en active IP Right Grant
2010
- 2010-02-08 TN TNP2010000068A patent/TN2010000068A1/fr unknown
- 2010-02-09 MA MA32605A patent/MA32665B1/fr unknown
- 2010-02-09 CO CO10014090A patent/CO6251371A2/es not_active Application Discontinuation
- 2010-02-09 EC EC2010009946A patent/ECSP109946A/es unknown
- 2010-08-18 JP JP2010183075A patent/JP5238000B2/ja active Active
- 2010-09-17 US US12/884,563 patent/US20110165153A1/en not_active Abandoned
- 2010-12-02 HK HK16108880.8A patent/HK1220708A1/zh unknown
2011
- 2011-06-24 CL CL2011001592A patent/CL2011001592A1/es unknown
- 2011-08-03 EC EC2011009946A patent/ECSP11009946A/es unknown
2012
- 2012-08-22 CL CL2012002329A patent/CL2012002329A1/es unknown
2013
- 2013-07-19 JP JP2013150731A patent/JP2014039541A/ja not_active Withdrawn
- 2013-08-23 US US13/974,230 patent/US20140004110A1/en not_active Abandoned
- 2013-08-23 US US13/974,226 patent/US9078879B2/en active Active
2014
- 2014-08-11 PH PH12014501812A patent/PH12014501812B1/en unknown
2015
- 2015-04-22 US US14/693,047 patent/US9932399B2/en active Active
2016
- 2016-01-12 CY CY20161100025T patent/CY1117101T1/el unknown
2017
- 2017-03-16 AR ARP170100658A patent/AR107902A2/es unknown
2018
- 2018-02-15 US US15/897,400 patent/US20180186876A1/en not_active Abandoned
2020
- 2020-11-04 US US17/088,765 patent/US20210230271A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW201512220A (zh)	2015-04-01
CN103396490A (zh)	2013-11-20
UA103005C2 (en)	2013-09-10
US20100189722A1 (en)	2010-07-29
IL202645A (en)	2016-03-31
PH12014501812A1 (en)	2016-10-24
UA105445C2 (en)	2014-05-12
CN101815725A (zh)	2010-08-25
UY31275A1 (es)	2009-03-31
CL2012002329A1 (es)	2012-12-21
CY1117101T1 (el)	2017-04-05
JP2014039541A (ja)	2014-03-06
PT2178915E (pt)	2016-02-04
US9932399B2 (en)	2018-04-03
WO2009019312A2 (fr)	2009-02-12
ZA200908758B (en)	2010-08-25
PL2178915T3 (pl)	2016-03-31
ECSP109946A (es)	2010-04-30
RS54359B1 (sr)	2016-04-28
CL2011001592A1 (es)	2012-02-17
KR101593403B1 (ko)	2016-02-12
AR071242A1 (es)	2010-06-09
PE20120259A1 (es)	2012-04-04
EP2562187A1 (fr)	2013-02-27
MA32665B1 (fr)	2011-10-02
ES2555202T3 (es)	2015-12-29
MY157555A (en)	2016-06-30
EP2178915A2 (fr)	2010-04-28
AU2008285590B2 (en)	2014-08-14
HUE026221T2 (en)	2016-05-30
EP2178915B1 (fr)	2015-10-14
US9078879B2 (en)	2015-07-14
IL202645A0 (en)	2011-08-01
EP2241577A1 (fr)	2010-10-20
ECSP11009946A (es)	2011-09-30
AU2008285590A1 (en)	2009-02-12
JP2010535483A (ja)	2010-11-25
CN105273086A (zh)	2016-01-27
SI2178915T1 (sl)	2016-01-29
PE20140196A1 (es)	2014-03-19
AR107902A2 (es)	2018-06-28
TWI535733B (zh)	2016-06-01
US20140010808A1 (en)	2014-01-09
US20140004110A1 (en)	2014-01-02
SG190657A1 (en)	2013-06-28
US20110165153A1 (en)	2011-07-07
CL2008002349A1 (es)	2009-10-23
ME02300B (me)	2016-06-20
PE20090499A1 (es)	2009-05-18
PH12014501812B1 (en)	2016-10-24
NZ583713A (en)	2012-07-27
CN102276724A (zh)	2011-12-14
EP2562187B1 (fr)	2019-03-27
CO6251371A2 (es)	2011-02-21
JP2011004758A (ja)	2011-01-13
HK1220708A1 (zh)	2017-05-12
US20160137729A1 (en)	2016-05-19
US20210230271A1 (en)	2021-07-29
EA201000274A1 (ru)	2010-10-29
KR20100054791A (ko)	2010-05-25
WO2009019312A3 (fr)	2009-04-30
JP5238000B2 (ja)	2013-07-17
EA027499B1 (ru)	2017-08-31
HRP20160009T1 (hr)	2016-02-12
BRPI0823331A2 (pt)	2013-07-30
CA2693464A1 (fr)	2009-02-12
TW200916478A (en)	2009-04-16
US20180186876A1 (en)	2018-07-05
DK2178915T3 (en)	2015-12-14
EA201200994A1 (ru)	2012-12-28
BRPI0815369A2 (pt)	2013-03-12
NZ600022A (en)	2013-11-29
CA2693464C (fr)	2017-10-24
JP5325216B2 (ja)	2013-10-23

Publication	Publication Date	Title
TN2010000068A1 (en)	2011-09-26	Anticorps anti-cd37
FR21C1064I1 (fr)	2022-02-18	Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
MA31606B1 (fr)	2010-08-02	Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
MA31605B1 (fr)	2010-08-02	Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
MA32804B1 (fr)	2011-11-01	Antagonistes d'isonicotinamide des récepteurs de l'orexine
MA31502B1 (fr)	2010-07-01	Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA33349B1 (fr)	2012-06-01	Compositions pharmaceutiques solides et procedes pour leur production
MA33815B1 (fr)	2012-12-03	Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
EA200901166A1 (ru)	2010-04-30	Соединения и композиции в качестве модуляторов активности gpr 119
SG10201405377XA (en)	2014-12-30	Compositions and methods for antibodies targeting complement protein c5
MA31822B1 (fr)	2010-11-01	Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues
EP2224955A4 (fr)	2011-02-16	Compositions et procédés pour la prévention et le traitement de l'arthrite
EP2073811A4 (fr)	2009-11-11	Inhibiteurs de kinase utiles pour le traitement de maladies myéloproliférantes et d'autres maladies proliférantes
MA30462B1 (fr)	2009-06-01	Composes de pyridylamide antagonistes des canaux calciques de type t
MA33534B1 (fr)	2012-08-01	Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
EP1848431A4 (fr)	2012-12-26	Formulations liquides pour le traitement de maladies ou affections
EP1967207A4 (fr)	2010-01-06	Inhibiteur de l'induction des cellules t cytotoxiques
MX2010003117A (es)	2010-04-01	Compuestos y composiciones como moduladores de la actividad de gpr119.
MA32132B1 (fr)	2011-03-01	Utilisation de ranolazine pour traiter la douleur
MA33241B1 (fr)	2012-05-02	Composes pour le traitement de troubles metaboliques
MX2011012015A (es)	2012-04-30	Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2009004757A (es)	2009-05-21	Moduladores de regeneracion neuronal.
EP2069377A4 (fr)	2009-11-11	Procédés et compositions pour le traitement de maladies et de troubles de la peau
MA34734B1 (fr)	2013-12-03	Nouvelle bactérie et extraits de ladite bactérie, et leur utilisation en dermatologie
WO2008123582A1 (fr)	2008-10-16	Composé de tétrahydroisoquinoline